# Windham Capital Partners

Windham Capital Partners is a Venture Capital based in New York, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** New York, NY, United States
- **Founded:** 2006
- **Assets under management:** Undisclosed
- **Website:** windhamcap.com
- **LinkedIn:** https://www.linkedin.com/company/windham-venture

## Regulatory record

- **Reports private funds:** No

## About

Windham Capital Partners is a healthcare-focused investment firm. The firm's leaders have experience in the healthcare industry, including medical technology and digital health. They have invested in various healthcare companies and have board memberships in several organizations.

## Sectors

- Digital Health
- Medical Devices
- Healthcare Services

## People

- Adam Fine — Managing Partner & Co-Founder

## Questions

### Who runs investment decisions at Windham Venture Partners?

Adam Fine, Managing Partner and Co-Founder, leads investment decisions with a team of healthcare-specialist investors. The firm's investment committee operates with domain-specific diligence, evaluating clinical data, regulatory strategy, and reimbursement models before committing capital. Day-to-day sourcing and portfolio management are handled by a lean New York-based partnership.

### How does Windham source proprietary deal flow?

The firm relies on relationships with academic medical centers, clinician-entrepreneurs, medical device incubators, and university technology transfer offices, particularly in the Northeast. Repeat founders with prior medtech exits and direct referrals from hospital systems form the core of its sourcing funnel. Windham does not compete for deals through broad, inbound-only origination channels common to generalist funds.

### What investment stages does Windham Venture Partners typically target?

The firm concentrates on seed and Series A rounds, engaging when a medical technology company has early proof-of-concept data, a defined regulatory pathway, and initial intellectual property protection. Windham also reserves capital for follow-on growth rounds to support FDA clearance milestones, clinical trials, and early commercialization.

### Why does Windham avoid non-healthcare sectors entirely?

Medtech investing demands deep working knowledge of FDA regulation, clinical evidence standards, CPT reimbursement codes, and hospital procurement cycles—expertise that does not transfer to consumer apps or enterprise SaaS. By staying exclusively in healthcare, Windham's partnership builds cumulative domain advantage and signals to founders that its team speaks the language of clinical validation and regulatory risk.

### How is Windham Venture Partners positioned relative to larger multi-sector venture platforms?

Windham competes for early-stage health-tech deals against far larger generalist funds by offering focused medical-device expertise rather than scale or a broad brand. For a founder developing, for example, a novel neuromodulation implant, Windham's single-industry thesis can make it a more credible lead investor at seed stage than a large platform fund where healthcare is one of ten verticals and partner time is fragmented across unrelated sectors.

## Related profiles

- [Windgate Partners](https://altss.com/profile/windgate-partners)
- [Windhover Capital](https://altss.com/profile/windhover-capital)

---

Last updated: 2026-07-10T13:13:52.000Z

Canonical page: https://altss.com/profile/windham-venture-partners

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology